Move Often eVery Day (MOV'D): An occupationally-tailored, remotely-delivered, socially-supported short exercise break intervention to decrease sedentary behavior in receptionist office staff

7.项目摘要/摘要。 久坐和不充分的中等强度到剧烈的体力活动(MVPA)是普遍存在的风险。 心血管疾病的因素1-6心血管疾病是全球主要的死亡原因，过早服用 每年655,000美国人的生命。7最近的研究表明，适度到剧烈运动的一些好处 体力活动可以通过一整天的2-5分钟的短时间的激励而积累起来 8-13确定有效的干预以中断 一天中长时间地坐着，短时间地吃2-5分钟的MVPA，这是一种运动零食，可以提供 对于久坐工作的成年人来说，改变两个心血管疾病风险因素是一种便捷的方法。目前的R34提议 用户测试和试点一种新的干预措施MOV‘D的可接受性、可行性和临床信号检测 与仅使用Fitbit的对照组相比，使用短时间MVPA可延长静坐时间。初步证据 来自NHLBI K01资助的概念验证研究发现，基于证据的行为改变技术 (BCT)向基于社交媒体的私人支持小组发送文本的步骤比发送给 仅Fitbit对照组，但效果并不持久。MOV通过以下方式显著增加了这一初始工作： 教授运动零食和BCT的视频，以增加初始和保持的变化；增加同伴教练 增加参与度的功能；瞄准运动零食而不是单一的运动回合；以及 高危、研究不足的人群(接待员和有心血管疾病危险因素的医务人员)。我们的团队 与斯坦福大学高级管理人员(低薪职位和高职位)合作 对身体活动的限制)。我们一起为MOV‘d计划量身定做了职业。在此之前 在进行全功率疗效试验(Orbit阶段III)时，我们需要进行用户测试并细化两种干预措施 与我们的目标人口构成部分(轨道第一阶段b；目标1)；并进行必要的可接受性， 可行性和临床信号检测试点试验(轨道第二阶段b；目标2)，将获得招募和 保留参数，以通知第三阶段试验。目标1-运动零食和BCT的用户测试 将与目标人群中的参与者一起制作视频，以确保学习效果， 适当性和可接受性。目标2飞行员将从目标中随机分配n=60名参与者 将患者分为MOV组或Fitbit组，为期6周，并进行6个月的随访。我们会比较一下 可接受性、可行性和临床信号检测的即时和6个月数据的先验基准 工作日延长了坐着的时间和工作日的MVPA分钟。建议的R34的结果将直接 通知R01进行MOV的第三阶段试验，以测试疗效和效果持续时间。长期目标 是拥有可扩展、可广泛访问、远程交付、低成本的行为干预，以减少心血管疾病 风险，而且很容易适应不同的人群。此外，我们将有一个经过审查的练习库 零食和BCT视频，以及为该领域的研究人员量身定做和改编视频的职业指南。

7. Project Summary / Abstract. Prolonged sitting and inadequate moderate to vigorous intensity physical activity (MVPA) are pervasive risk factors for cardiovascular disease (CVD).1–6 CVD is the leading cause of death globally, prematurely taking 655,000 American lives annually.7 Recent research has shown that some benefits of moderate to vigorous physical activity can be accrued in motivationally accessible, short, 2-5 minute bouts throughout the day rather than needing to be a single, longer, continuous bout.8–13 Identifying an effective intervention to interrupt prolonged sitting throughout the day with short, 2-5 minute bouts of MVPA, “exercise snacks,” can provide an accessible way for adults with sedentary jobs to change two CVD risk factors. The current R34 proposes to user-test and pilot the acceptability, feasibility, and clinical signal detection of a novel intervention, MOV’D, to interrupt prolonged sitting with short bouts of MVPA, compared with a Fitbit-only control. Preliminary evidence from an NHLBI K01-funded proof-of-concept study found that evidence-based behavior change technique (BCT) texts to a private, social-media based support group increased steps throughout the day compared to a Fitbit-only control group, but the effects did not last. MOV’D significantly adds to this initial work by: adding videos teaching exercise snacks and BCTs to increase initial and maintained change; adding a peer-coach feature to increase engagement; targeting exercise snacks instead of single exercise bouts; and targeting an at-risk, understudied population (receptionists and clerical health care staff with CVD risk factors). Our team partnered with upper management of Stanford clerical health care staff (low wage positions with high job constraints on physical activity). Together, we have occupationally-tailored the MOV’D program. Before conducting a fully-powered efficacy trial (ORBIT Phase III), we need to user-test and refine two intervention components with our target population (ORBIT Phase Ib; Aim 1); and conduct the necessary acceptability, feasibility, and clinical signal detection pilot trial (ORBIT Phase IIb; Aim 2), which will obtain recruitment and retention parameters to inform the Phase III trial. The Aim 1 user-testing of both the exercise snack and BCT videos will be done with participants from the target population to ensure learning effectiveness, appropriateness, and acceptability. The Aim 2 pilot will randomly assign n=60 participants from the target population to either MOV’D or a Fitbit-only control for 6-weeks, with a 6-month follow-up. We will compare immediate and 6-month data to a priori benchmarks for acceptability, feasibility, and clinical signal detection in workday prolonged sitting bout length and workday MVPA minutes. Results from the proposed R34 will directly inform the R01 for the Phase III trial of MOV’D to test efficacy and duration of effects. The long-term objective is to have a scalable, widely-accessible, remotely-delivered, low-cost behavioral intervention to decrease CVD risk, and is easily adaptable to different populations. Additionally, we will have a library of vetted exercise snack and BCT videos and a guide for occupational-tailoring and adapting videos for researchers in this space.